Nanobiotix is exploding higher today despite a lack of company-specific news or recent filings to explain the move. The stock is currently trading well below its 50-day moving average, suggesting this volatility may be a technical correction rather than a fundamental shift. In the absence of internal catalysts, the shares appear to be participating in broader momentum within the biotechnology sector, which has seen increased attention surrounding oncology-focused clinical data presentations at the ESMO 2026 congress.